Why Is COGENT BIOSCIENCES I (COGT) Stock Down Today?
By the Top Tier Newswire AI Desk · August 11, 2026 at 10:16 AM ET · reviewed against 6 wire stories
COGENT BIOSCIENCES I (COGT) is down -5.66% in the latest session. Our newswire has captured 6 stories on COGT across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Cogent Biosciences Inc. stock COGT fell 5.66% to $39.18 in morning trading on August 10, 2026. The decline followed the company’s announcement of a $400 million at-the-market equity offering. The move signaled increased capital-raising activity amid ongoing development of its drug candidate bezuclastinib.
What Happened
The stock opened at $41.06, down 1.1% from the prior close, and fell further to a session low of $39.05 before stabilizing near $39.18. The decline came after Cogent filed a prospectus supplement with the SEC for the at-the-market offering. The 8-K filing detailed the offering and included financial statements and exhibits. The announcement followed recent regulatory and clinical progress, including the submission of a New Drug Application for bezuclastinib in advanced systemic mastocytosis and the potential for approval in gastrointestinal stromal tumor and non-advanced systemic mastocytosis by year-end. Despite these developments, the equity offering raised concerns about dilution and weighed on investor sentiment.
What The Data Shows
The stock has traded between $10.70 and $43.73 over the past 52 weeks. With a market capitalization of $7.1 billion and a trailing twelve-month EPS of -2.51, the company remains unprofitable. The session volume of 0.6 million shares is below the 3-month average, indicating limited immediate retail participation. Recent insider or congressional transactions were not reported. The 30-day average sentiment score was 52/100, but it fell to 48/100 over the last week, reflecting a shift toward caution.
What To Watch
Cogent Biosciences is on track for potential regulatory decisions on bezuclastinib later this year. Investors will be watching for further updates on the drug’s approval timeline and the impact of the equity offering on the company’s capital structure.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
COGT · today's session (5-min) · -6.57% vs prior close · updated 2:44 PM ETAI sentiment, last 36h · averaged over 6 stories · 54/100 neutral
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
19h agoTipRanksBEARISH 28General
Cogent Biosciences Announces $400 Million ATM Offering
An update from Cogent Biosciences ( ($COGT) ) is now available. On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Ex...
21h agoSEC 8-KNEUTRAL 50General
Cogent Biosciences, Inc. (COGT) files 8-K
Filed: 2026-08-10 AccNo: 0001193125-26-342695 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
1d agoMarketChameleonBULLISH 73Product/PR
Cogent Biosciences Achieves Key Milestones with Bezuclastinib, Maintains Strong Cash Position Through 2028
August 10, 2026
Cogent Biosciences reaches pivotal regulatory and clinical milestones with bezuclastinib for GIST and systemic mastocytosis, supported by a solid cash runway. Detailed Phase 3 results show significant clinical benefit, corporate expansion is underway, and multiple new drug applications are progressing.
1d agoSeeking AlphaNEUTRAL 50Earnings
Cogent Biosciences reports Q2 results
1d agoSEC 8-KNEUTRAL 50General
Cogent Biosciences, Inc. (COGT) files 8-K
Filed: 2026-08-10 AccNo: 0001193125-26-341315 Size: 375 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
1d agoBusiness InsiderBULLISH 73Product/PR
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →